Navigation Links
Aptuit Completes Sale of CTS to Catalent; Reinforces Commitment to Scientific Excellence and Most Comprehensive Early to Mid-Phase Development Capability

GREENWICH, Conn., Feb. 17, 2012 /PRNewswire/ -- Aptuit announces the completion of the sale of the Clinical Trials Supply business to Catalent Pharma Solutions on February 17, 2012.  Timothy C. Tyson, Chairman and CEO of Aptuit, LLC stated that Aptuit will continue to deliver scientific and service excellence to provide integrated capabilities for the early to mid phase drug development markets.

(Logo: )

Mr. Tyson explained, "We have assembled a team comprised of some of the foremost scientific professionals in the industry. As part of our ongoing mission to engineer a better drug development process, we previously implemented a service performance initiative that drives every level of our organization. Today, Aptuit people are joining their 'heads for science' and their 'hearts for service' to continue to provide scientific excellence and a level of service that goes above and beyond what has come to be the industry standard."

Early to mid-phase services
Aptuit's early to mid-phase development services include Drug Design and Discovery, Solid State Chemistry, Preclinical Biosciences, API Development and Manufacture, Solid, Oral and Sterile Dosage Formulation, Clinical Sciences, Consulting Services and Aptuit INDiGO™, our proprietary program for fast track IND submission. Mr. Tyson noted Aptuit's best in class position in several of these key development areas, specifically citing the company's solid state chemistry, high potency API, accelerated development and lead optimization capabilities. 

Integrated or stand alone services
Stuart E. Needleman, President, Aptuit Scientific Operations, stressed that Aptuit has a team of scientific professionals in place who speak the client's language. He explained that they have extensive experience in working with multinational clients and emerging biotechs, and a track record for delivering on time and in full. "We thoroughly understand that business goals and scientific objectives vary greatly from client to client. That's why we are flexible in offering our clients an Integrated Service Package, consisting of all-inclusive early to mid-phase development services from a single Aptuit location, or stand alone services that are tailored to precisely meet their unique requirements," said Mr. Needleman.

The global scientific team led by a new CSO
The appointment of a Chief Scientific Officer (CSO) was cited as an example of the company's focus on scientific excellence. Mr. Needleman said, "The recent appointment of Dr. Jan-Olav Henck, a world renowned solid state chemist with significant industry experience, is another indication of how Aptuit customers benefit from the leadership and collaboration of some of the industry's most distinguished and experienced scientific minds." He further explained that while Aptuit scientists offer drug development expertise across all therapeutic areas, the company includes technical teams of scientific medical specialists who are focused on diseases and therapies that drive the current market, including neuroscience, cardiovascular, oncology and infectious disease.

In discussing Aptuit's strategically positioned global resources, Mr. Needleman cited Aptuit's world class drug design and optimization facility in Verona, Italy. "While the special strengths of some of our individual global facilities such as Verona are a decided advantage, we are a capability-centric organization: we focus on our client's needs," said Mr. Needleman. He added that all sites adhere to the same high quality standards of regulatory compliance.

In conclusion, Mr. Tyson said, "Aptuit continues to be a world-leading pharmaceutical services company, well-positioned for the dynamic growth projected in this market.  We plan to invest for growth, continue our passion for scientific excellence and deliver on exceptional customer service."

For more information, please contact Maria Garvey, Delfino Marketing at 914-747-1400 or or Paul Delfino at 914-494-4679 or email him at

Aptuit is a global pharmaceutical services company focusing on delivering contract development and manufacturing services and streamlining the drug development process for biotechnology and pharmaceutical innovators. Aptuit's employees deliver an integrated suite of product development services to more than 800 companies worldwide driven by a deep commitment to client service, quality and an unrivaled track record of scientific excellence. The company is partnered with Welsh, Carson, Anderson & Stowe, one of the world's leading private equity investors. For more information about Aptuit, visit

Aptuit: engineering a better drug development process through scientific excellence

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Celladon Corporation Completes $43 Million Financing to Advance MYDICAR® for the Treatment of Heart Failure
2. Hill-Rom Completes Acquisition of Volker
3. Positron Completes Agreement With Institute of Nuclear Research, Troitsk, Russia for Additional Strontium-82 Supply
4. Mylan Completes Acquisition of Two Limited-Competition Dermatological Products from Valeant
5. Valeant Pharmaceuticals Completes Divestiture of Generic Dermatology Products to Mylan
6. Sigma-Aldrich Completes Acquisition of BioReliance
7. China Nuvo Solar Energy, Inc. Completes Name Change to SurgLine International, Inc.
8. Enlivex Completes Patient Enrollment in its Phase I/II Clinical Trial
9. ULURU Inc. Completes Altrazeal® License Agreement for Europe
10. FDA Completes Work on Three Drug User Fee Programs
11. Respironics, Inc. Completes Voluntary Recall Notification of a Limited Number of Trilogy 100 Ventilators
Post Your Comments:
(Date:10/12/2015)...  In a Sutter Institute of Medical Research study ... and Psychiatry, the blood product intravenous immunoglobulin, or IVIG, ... in patients in the early, pre-dementia phase of Alzheimer,s ... IVIG, extracted from the plasma of more than 1,000 ... protein found in patients with Alzheimer,s disease. Sutter Institute ...
(Date:10/12/2015)... 2015 Leadership of the National Association of Vision ... Aspasia Shappet , CEO of MESVision resumed her role ... Board at its annual strategic planning meeting in ... of the organization from May 2013 to May of this ... as a result of the increased demands of his recent ...
(Date:10/12/2015)... 12, 2015  CME Group,s Center for Innovation ... of Theranos, is the 11 th recipient of the ... revolutionary blood diagnostics company, Theranos , to change health ... a new era of preventive care. CME Group will present ... Conference in Naples, Florida , on ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... ... In an age where the cost of energy is rising, Susquehanna ... in 2009. The Williamsport Regional Medical Center (WRMC) campus has grown 50 percent since ... , According to Facilities Management Administrative Director Dieter Reichmann, this is the result ...
(Date:10/13/2015)... ... October 13, 2015 , ... NavaFit Inc. today announced the ... others to train with, participate in local fitness & sporting events, and stay ... , “As high medical costs drive us to get more serious about fitness and ...
(Date:10/13/2015)... ... October 13, 2015 , ... Altec Products, Inc., ... Sponsorship of Synergy 2015. The annual WennSoft KEY2ACT user conference will take place ... will unite customers, partners, WennSoft team members and sponsors to facilitate the sharing ...
(Date:10/13/2015)... ... October 13, 2015 , ... Georgia Partnership for TeleHealth ... throughout Georgia, along with affiliate organizations, Alabama Partnership for Telehalth (ATP) and Florida ... for Fall 2015. , Each of the three conferences share this year’s ...
(Date:10/13/2015)... ... October 13, 2015 , ... Local Gold’s Gym franchise owner, Bryce Berry, ... August 26. Berry, who owns and operates Gold's Gym Cheyenne in Cheyenne, ... Gyms in the United States. A brand leader in global fitness, Gold’s Gyms are ...
Breaking Medicine News(10 mins):